Cindy S Starbuck

US Patent:

8288440, Oct 16, 2012

Filed:

Jan 13, 2010

Appl. No.:

12/686812

Inventors:

Jeannie Chow Wong - Chicago IL, US
Aaron S. Cote - West Windsor NJ, US
Erik A. Dienemann - Metuchen NJ, US
Kimberly Gallagher - Green Lane PA, US
Craig Ikeda - Harleysville PA, US
Justin Moser - Collegeville PA, US
Pavol Rajniak - Lansdale PA, US
Robert A. Reed - Line Lexington PA, US
Cindy Starbuck - Branchburg NJ, US
Hsien-Hsin Tung - Edison NJ, US
Qingxi Wang - Ambler PA, US
Benjamin Max Cohen - Cranford NJ, US
Vincent R. Capodanno - Hillsborough NJ, US
Brian Sell - Royersford PA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/19

US Classification:

514575

Abstract:

The present invention provides a pharmaceutical composition or crystalline composition with a specific dissolution profile, which comprises suberoylanilide hydroxamic acid or a pharmaceutically acceptable salt or hydrate thereof as an active ingredient. The present invention provides a process of producing said crystalline composition or pharmaceutical composition. The present invention also provides compositions with a specific particle size distribution.

US Patent:

8450372, May 28, 2013

Filed:

Jan 13, 2010

Appl. No.:

12/686843

Inventors:

Jeannie Chow Wong - Chicago IL, US
Aaron S. Cote - West Windsor NJ, US
Erik A. Dienemann - Metuchen NJ, US
Kimberly Gallagher - Green Lane PA, US
Craig Ikeda - Harleysville PA, US
Justin Moser - Collegeville PA, US
Pavol Rajniak - Lansdale PA, US
Robert A. Reed - Line Lexington PA, US
Cindy Starbuck - Branchburg NJ, US
Hsien-Hsin Tung - Edison NJ, US
Qingxi Wang - Ambler PA, US
Benjamin Max Cohen - Cranford NJ, US
Vincent R. Capodanno - Hillsborough NJ, US
Brian Sell - Royersford PA, US
Thomas A. Miller - Wakefield MA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/19

US Classification:

514575

Abstract:

The present invention provides a pharmaceutical composition or crystalline composition with a specific dissolution profile, which comprises suberoylanilide hydroxamic acid or a pharmaceutically acceptable salt or hydrate thereof as an active ingredient. The present invention provides a process of producing said crystalline composition or pharmaceutical composition. The present invention also provides compositions with a specific particle size distribution.

US Patent:

20080132575, Jun 5, 2008

Filed:

May 16, 2006

Appl. No.:

11/663165

Inventors:

Jeannie Chow Wong - Chicago IL, US
Aaron S. Cote - West Windsor NJ, US
Erik A. Dienemann - Metuchen NJ, US
Kimberly Gallagher - Green Lane PA, US
Craig Ikeda - Harleysville PA, US
Justin Moser - Collegeville PA, US
Pavol Rajniak - Lansdale PA, US
Robert A. Reed - Line Lexington PA, US
Cindy Starbuck - Branchburg NJ, US
Hsien-Hsin Tung - Edison NJ, US
Qingxi Wang - Ambler PA, US
Benjamin Max Cohen - Cranford NJ, US
Vincent R. Capodanno - Hillsborough NJ, US
Brian Sell - Royersford PA, US
Thomas A. Miller - Brookline MA, US

International Classification:

A61K 31/185
A61P 35/00

US Classification:

514575

Abstract:

The present invention provides a pharmaceutical composition or crystalline composition with a specific dissolution profile, which comprises suberoylanilide hydroxamic acid or a pharmaceutically acceptable salt or hydrate thereof as an active ingredient. The present invention provides a process of producing said crystalline composition or pharmaceutical composition. The present invention also provides compositions with a specific particle size distribution.

US Patent:

20090087492, Apr 2, 2009

Filed:

Mar 12, 2007

Appl. No.:

12/282043

Inventors:

Brian K. Johnson - Princeton NJ, US
Hsien Hsin Tung - Edison NJ, US
Ivan Lee - Piscataway NJ, US
Aaron S. Cote - West Windosr NJ, US
Cindy Starbuck - Branchburg NJ, US
Michael Midler - Monroe Township NJ, US

Assignee:

MERCK & CO., INC. - Rahway NJ

International Classification:

A61K 9/14
C07F 9/02
A61K 31/66

US Classification:

424489, 568 15, 514 75

Abstract:

The present invention relates to a process, for the production of crystalline particles of an active organic compound The process includes the steps of generating a micro-seed by a wet-milling process and subjecting the micro-seed to a crystallization process. The resulting crystalline particles have a mean particle size of less than about 100 μm. The present invention also provides for a pharmaceutical composition which includes the crystalline particles produced by the method described herein and a pharmaceutically acceptable carrier.